1887

Chapter 25 : Hepatitis C Virus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Hepatitis C Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819156/9781555819149.ch25-1.gif /docserver/preview/fulltext/10.1128/9781555819156/9781555819149.ch25-2.gif

Abstract:

Hepatitis C virus (HCV) is a single-stranded RNA virus that was not known as a causative agent of acute and chronic hepatitis until 1989. The development of blood transfusion technology in the mid-20th century led to its rapid spread into new populations with enormous disease burden due to cirrhosis and hepatocellular carcinoma (1, 2). Its discovery by reverse molecular genetics is one of the major achievements of modern medicine and a model for the discovery of many other pathogens during the past 25 years (3). Unlike hepatitis B virus (HBV) and human immunodeficiency virus (HIV), which establish permanent chronic infection, HCV is spontaneously cleared in some individuals and is also amenable to therapeutic cure. With advances in drug therapies, all HCV infections are potentially curable. The development of technologies for viral discovery and clinical detection and monitoring, as well as new classes of antiviral therapy, are important components of the HCV legacy.

Citation: Mallory M, Hillyard D. 2016. Hepatitis C Virus, p 351-361. In Loeffelholz M, Hodinka R, Young S, Pinsky B (ed), Clinical Virology Manual, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819156.ch25
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

HCV Viral Genome Organization

Citation: Mallory M, Hillyard D. 2016. Hepatitis C Virus, p 351-361. In Loeffelholz M, Hodinka R, Young S, Pinsky B (ed), Clinical Virology Manual, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819156.ch25
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819156.ch25
1. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. 2008. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology 47:11281135.[PubMed]
2. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int 29(Suppl 1):7481.[PubMed]
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359362.[PubMed]
4. Lindenbach B, Murray C, Thiel HJ, Rice C,. 2013. Hepatitis C virus, p 712746. In Knipe D, Howley P (ed), Field Virology, Vol. Lippincott Williams and Wilkins, Philadelphia.
5. Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, Hofgärtner WT, Carithers RL Jr, McMahon BJ, Mullins JI, Corey L, Gretch DR. 1998. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 72:42884296.[PubMed]
6. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat Rev Microbiol 5:453463.[PubMed]
7. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318327.[PubMed]
8. Gómez J, Martell M, Quer J, Cabot B, Esteban JI. 1999. Hepatitis C viral quasispecies. J Viral Hepat 6:316.[PubMed]
9. Spengler U, Nischalke HD, Nattermann J, Strassburg CP. 2013. Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol 19:78527866.[PubMed]
10. van de Laar TJ, Paxton WA, Zorgdrager F, Cornelissen M, de Vries HJ. 2011. Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis 38:102104.[PubMed]
11. Thomas DL. 2013. Global control of hepatitis C: where challenge meets opportunity. Nat Med 19:850858.[PubMed]
12. Seeff LB. 1991. Hepatitis C from a needlestick injury. Ann Intern Med 115:411.[PubMed]
13. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107115.[PubMed]
14. Strickland GT. 2006. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 43:915922.[PubMed]
15. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705714.[PubMed]
16. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. 2014. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160:293300.[PubMed]
17. Backus LI, Belperio PS, Loomis TP, Mole LA. 2014. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health 104(Suppl 4):S555S561.[PubMed]
18. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. 2013. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 158:101108.[PubMed]
19. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:7787.[PubMed]
20. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529538.[PubMed]
21. Maasoumy B, Wedemeyer H. 2012. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26:401412.[PubMed]
22. Tsoulfas G, Goulis I, Giakoustidis D, Akriviadis E, Agorastou P, Imvrios G, Papanikolaou V. 2009. Hepatitis C and liver transplantation. Hippokratia 13:211215.[PubMed]
23. Chen SL, Morgan TR. 2006. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3:4752.[PubMed]
24. Pawlotsky JM. 2010. More sensitive hepatitis C virus RNA detection: what for? J Hepatol 52:783785.[PubMed]
25. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. 2016. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3:314.[PubMed]
26. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967972.[PubMed]
27. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. 2015. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62(Suppl):S87S99.[PubMed]
28. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M. 2001. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 183:11951203.[PubMed]
29. Itakura J, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Itakura Y, Tamaki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Takahashi Y, Maekawa S, Enomoto N, Izumi N. 2015. Resistance-associated NS5A variants of hepatitis C virus are susceptible to interferon-based therapy. PLoS One 10:e0138060.[PubMed]
30. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJPROVE1 Study Team. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:18271838.[PubMed]
31. Keating GM. 2014. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs 74:11271146.[PubMed]
32. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P. 2010. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52:652657.[PubMed]
33. Attar BM, Van Thiel DH. 2016. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 7:3340.[PubMed]
34. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. 2014. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 20:96339652.[PubMed]
35. Liang TJ. 2013. Current progress in development of hepatitis C virus vaccines. Nat Med 19:869878.[PubMed]
36. Selvarajah S, Busch MP. 2012. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther 17(7 Pt B):14231429.[PubMed]
37. Bruggmann P. , et al. 2014. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 21(Suppl 1):533.[PubMed]
38. Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. 1995. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health 85:15311537.[PubMed]
39. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. 2005. Dynamics of viremia in early hepatitis C virus infection. Transfusion 45:9941002.[PubMed]
40. Dufour DR, Talastas M, Fernandez MD, Harris B. 2003. Chemiluminescence assay improves specificity of hepatitis C antibody detection. Clin Chem 49:940944.[PubMed]
41. Kim S, Kim JH, Yoon S, Park YH, Kim HS. 2008. Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection. J Clin Microbiol 46:39193923.[PubMed]
42. Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. 2014. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 20:34313442.[PubMed]
43. Bendinelli M, Pistello M, Maggi F, Vatteroni M,. 2009. Blood-borne hepatitis viruses: Hepatitis viruses B, C, and D and candidate agents of cryptogenetic hepatitis, p 325362. In Wiedbrauk DL (ed), Specter S, Hodinka RL, 4th ed. Clinical Virology Manual, ASM Press, Washington, DC.
44. Martin P, Fabrizi F, Dixit V, Quan S, Brezina M, Kaufman E, Sra K, DiNello R, Polito A, Gitnick G. 1998. Automated RIBA hepatitis C virus (HCV) strip immunoblot assay for reproducible HCV diagnosis. J Clin Microbiol 36:387390.[PubMed]
45. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 200352:113,.
46. Gong S, Schmotzer CL, Zhou L. 2015. Evaluation of quantitative real-time PCR as a hepatitis C virus supplementary test after RIBA discontinuation. J Clin Lab Anal, in press.[PubMed]
47. Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. 2003. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol 41:32123220.[PubMed]
48. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. 2012. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 22:156165[CrossRef].[PubMed]
49. Chevaliez S, Pawlotsky JM. 2012. Virology of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 26:381389.[PubMed]
50. Ghany MG, Strader DB, Thomas DL, Seeff LBAmerican Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:13351374.[PubMed]
51. Kohli A, Shaffer A, Sherman A, Kottilil S. 2014. Treatment of hepatitis C: a systematic review. JAMA 312:631640.[PubMed]
52. Pawlotsky JM. 2014. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:11761192.[PubMed]
53. Cento V, Chevaliez S, Perno CF. 2015. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS 10:381389.[PubMed]
54. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. 2014. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 108:181191.[PubMed]
55. OLYSIO Prescribing Information. Janssen Therapeutics. Titusville, NJ, USA. Available at: http://www.olysio.com/shared/product/olysio/prescribing-information.pdf Accessed 15 April 2016.
56. Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. 2012. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 7:e39652.[PubMed]
57. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979987.[PubMed]
58. Sarrazin C, Dragan A, Gärtner BC, Forman MS, Traver S, Zeuzem S, Valsamakis A. 2008. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 43:162168.[PubMed]
59. Zepatier US Prescribing Information. Merck & Co Inc., Kenilworth, NJ, USA. Available at: https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 16 Apr 2016.
60. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399401.[PubMed]
61. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:11051109.[PubMed]
62. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798801.[PubMed]
63. Ismail N, Fish GE, Smith MB. 2004. Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus. J Clin Microbiol 42:610617.[PubMed]
64. Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. 2005. Performance characteristics of the ARCHITECT anti-HCV assay. J Clin Virol 34:97103.[PubMed]
65. Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, Colucci G, Smedile A, Ghisetti V. 2008. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol 80:254260.[PubMed]
66. Vermehren J, Kau A, Gärtner BC, Göbel R, Zeuzem S, Sarrazin C. 2008. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46:38803891.[PubMed]
67. Pyne MT, Hillyard DR. 2013. Evaluation of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test. Diagn Microbiol Infect Dis 77:2530.[PubMed]
68. Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH. 2007. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 38:96100.[PubMed]
69. Akhavan S, Ronsin C, Laperche S, Thibault V. 2011. Genotype 4 hepatitis C virus: beware of false-negative RNA detection. Hepatology 53:10661067.[PubMed]
70. Chevaliez S, Bouvier-Alias M, Castéra L, Pawlotsky JM. 2009. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 49:13971398.[PubMed]
71. Germer JJ, Bommersbach CE, Schmidt DM, Bendel JL, Yao JD. 2009. Quantification of genotype 4 hepatitis C virus RNA by the COBAS AmpliPrep/COBAS TaqMan hepatitis C virus test. Hepatology 50:16791680.
72. Halfon P, Martinot-Peignoux M, Khiri H, Marcellin P. 2010. Quantification of genotype 4 serum samples: impact of hepatitis C virus genetic variability. Hepatology 52:401.[PubMed]
73. Chevaliez S, Bouvier-Alias M, Rodriguez C, Soulier A, Poveda JD, Pawlotsky JM. 2013. The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol 51:10781082.[PubMed]
74. Pas S, Molenkamp R, Schinkel J, Rebers S, Copra C, Seven-Deniz S, Thamke D, de Knegt RJ, Haagmans BL, Schutten M. 2013. Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J Clin Microbiol 51:238242.[PubMed]
75. Pyne MT, Mallory M, Hillyard DR. 2015. HCV RNA measurement in samples with diverse genotypes using versions 1 and 2 of the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV test. J Clin Virol 65:5457.[PubMed]
76. Vermehren J, Colucci G, Gohl P, Hamdi N, Abdelaziz AI, Karey U, Thamke D, Zitzer H, Zeuzem S, Sarrazin C. 2011. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol 49:33093315.[PubMed]
77. Zitzer H, Heilek G, Truchon K, Susser S, Vermehren J, Sizmann D, Cobb B, Sarrazin C. 2013. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 51:571577.[PubMed]
78. Pawlotsky JM. 2002. Use and interpretation of virological tests for hepatitis C. Hepatology 36(Suppl 1):S65S73[CrossRef].[PubMed]
79. Hraber PT, Fischer W, Bruno WJ, Leitner T, Kuiken C. 2006. Comparative analysis of hepatitis C virus phylogenies from coding and non-coding regions: the 5′ untranslated region (UTR) fails to classify subtypes. Virol J 3:103[CrossRef].[PubMed]
80. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962973.[PubMed]
81. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. 1994. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 75:10531061.[PubMed]
82. Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, Sabbah S. 2007. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 45:11021112.[PubMed]
83. Molenkamp R, Harbers G, Schinkel J, Melchers WJ. 2009. Identification of two Hepatitis C Virus isolates that failed genotyping by Versant LiPA 2.0 assay. J Clin Virol 44:250253.[PubMed]
84. Cento V, Landonio S, De Luca F, Di Maio VC, Micheli V, Mirabelli C, Niero F, Magni C, Rizzardini G, Perno CF, Ceccherini-Silberstein F. 2013. A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Antivir Ther 18:645648.[PubMed]
85. Martró E, González V, Buckton AJ, Saludes V, Fernández G, Matas L, Planas R, Ausina V. 2008. Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5′ noncoding and nonstructural 5b genomic regions. J Clin Microbiol 46:192197.[PubMed]
86. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. 2009. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 4:e8209.[PubMed]
87. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrère JJ, Pawlotsky JM, De Micco P, Laperche S. 2007. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45:11401145.[PubMed]
88. Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol 510:3353.[PubMed]
89. Benedet M, Adachi D, Wong A, Wong S, Pabbaraju K, Tellier R, Tang JW. 2014. The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis. J Clin Virol 60:301304.[PubMed]
90. González V, Gomes-Fernandes M, Bascuñana E, Casanovas S, Saludes V, Jordana-Lluch E, Matas L, Ausina V, Martró E. 2013. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. J Clin Virol 58:249253.[PubMed]
91. Hong SK, Cho SI, Ra EK, Kim EC, Park JS, Park SS, Seong MW. 2012. Evaluation of two hepatitis C virus genotyping assays based on the 5′ untranslated region (UTR): the limitations of 5′ UTR-based assays and the need for a supplementary sequencing-based approach. J Clin Microbiol 50:37413743.[PubMed]
92. Larrat S, Poveda JD, Coudret C, Fusillier K, Magnat N, Signori-Schmuck A, Thibault V, Morand P. 2013. Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0. J Clin Microbiol 51:28152821.[PubMed]
93. Mallory MA, Lucic DX, Sears MT, Cloherty GA, Hillyard DR. 2014. Evaluation of the Abbott realtime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. J Clin Virol 60:2226.[PubMed]
94. Andonov A, Chaudhary RK. 1995. Subtyping of hepatitis C virus isolates by a line probe assay using hybridization. J Clin Microbiol 33:254256.[PubMed]
95. De Keukeleire S, Descheemaeker P, Reynders M. 2015. Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERSANT HCV Genotype 2.0 assay. Diagn Microbiol Infect Dis 82:201202.[PubMed]
96. Cai Q, Zhao Z, Liu Y, Shao X, Gao Z. 2013. Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. Int J Mol Med 31:347352.[PubMed]
97. Ciotti M, Marcuccilli F, Guenci T, Babakir-Mina M, Chiodo F, Favarato M, Perno CF. 2010. A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. J Virol Methods 167:205207.[PubMed]
98. Noppornpanth S, Sablon E, De Nys K, Truong XL, Brouwer J, Van Brussel M, Smits SL, Poovorawan Y, Osterhaus AD, Haagmans BL. 2006. Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5′ untranslated regions. J Clin Microbiol 44:39693974.[PubMed]
99. Shinol RC, Gale HB, Kan VL. 2012. Performance of the Abbott RealTime HCV Genotype II RUO assay. J Clin Microbiol 50:30993101.[PubMed]
100. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M. 2008. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 46:19011906.[PubMed]
101. Mokhtari C, Ebel A, Reinhardt B, Merlin S, Proust S, Roque-Afonso AM. 2016. Characterization of Samples identified as hepatitis C virus Genotype 1 without subtype by Abbott RealTime HCV Genotype II assay using the new Abbott HCV Genotype Plus RUO Test. J Clin Microbiol 54:296299.[PubMed]
102. Sam SS, Steinmetz HB, Tsongalis GJ, Tafe LJ, Lefferts JA. 2013. Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. Exp Mol Pathol 95:1822.[PubMed]
103. Khuroo MS, Khuroo NS, Khuroo MS. 2015. Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis. PLoS One 10:e0121450.[PubMed]
104. Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, Beeching NJ, Zijlstra EE. 2008. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 57:7277.[PubMed]
105. Smith BD, Jewett A, Drobeniuc J, Kamili S. 2012. Rapid diagnostic HCV antibody assays. Antivir Ther 17(7 Pt B):14091413.[PubMed]
106. Smith BD, Teshale E, Jewett A, Weinbaum CM, Neaigus A, Hagan H, Jenness SM, Melville SK, Burt R, Thiede H, Al-Tayyib A, Pannala PR, Miles IW, Oster AM, Smith A, Finlayson T, Bowles KE, Dinenno EA. 2011. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 53:780786.[PubMed]
107. Daniel HD, Abraham P, Raghuraman S, Vivekanandan P, Subramaniam T, Sridharan G. 2005. Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies. J Clin Microbiol 43:19771978.[PubMed]
108. Scheiblauer H, El-Nageh M, Nick S, Fields H, Prince A, Diaz S. 2006. Evaluation of the performance of 44 assays used in countries with limited resources for the detection of antibodies to hepatitis C virus. Transfusion 46:708718.[PubMed]
109. Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hézode C, Pawlotsky JM. 2016. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect 22:459.e1459.e6.[PubMed]
110. American Association for the Study of Liver Diseases, 2016. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C Available at: http://hcvguidelines.org/full-report-view. Accessed March, 15.

Tables

Generic image for table
TABLE 1

Commercial anti-HCV screening assays

Citation: Mallory M, Hillyard D. 2016. Hepatitis C Virus, p 351-361. In Loeffelholz M, Hodinka R, Young S, Pinsky B (ed), Clinical Virology Manual, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819156.ch25
Generic image for table
TABLE 2

Commercial HCV RNA tests

Citation: Mallory M, Hillyard D. 2016. Hepatitis C Virus, p 351-361. In Loeffelholz M, Hodinka R, Young S, Pinsky B (ed), Clinical Virology Manual, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819156.ch25

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error